bioAffinity Technologies (BIAF) Cash from Financing Activities (2021 - 2026)

bioAffinity Technologies has disclosed Cash from Financing Activities across 6 years of filings, most recently posting -$118513.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 111.48% year-over-year to -$118513.0; the TTM figure through Mar 2026 stood at $13.6 million (up 192.71% YoY), while the FY2025 annual figure was $14.7 million, up 161.82% from the prior year.
• Cash from Financing Activities eased to -$118513.0 in Q1 2026, from $1.3 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for BIAF reached as high as $15.0 million in Q3 2022 and fell as low as -$563556.0 in Q4 2022.
• The 5-year median for Cash from Financing Activities is $301363.0 (2022), against an average of $2.0 million.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 131.85% — and 2025, when it jumped 3412.08%.
• A 5-year view of Cash from Financing Activities shows it stood at -$563556.0 in 2022, then soared by 84.95% to -$84805.0 in 2023, then jumped by 2488.86% to $2.0 million in 2024, then slumped by 33.85% to $1.3 million in 2025, then slumped by 108.84% to -$118513.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$118513.0, $1.3 million, and $9.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.